万拉法新与阿米替林治疗老年期抑郁症对照研究

目的 探讨万拉法新治疗老年期抑郁症的疗效和安全性。方法 将62例老年期抑郁症患者随机分为研究组(万拉法新治疗)和对照组(阿米替林治疗)，每组各31例，进行6w的双盲对照研究；于治疗前及治疗第2、4、6w末采用汉米尔顿抑郁量表、临床总体量表一疗效总评量表评定临床疗效，副反应量表评定药物不良反应。结果 万拉法新与阿米替林疗效相当，万拉法新起效快于阿米替林，不良反应较轻。结论 万拉法新是一种治疗老年期抑郁症疗效显著、依从性好、不良反应较轻、安全性好的抗抑郁剂，值得临床推广。

A control study of venlafaxine and amitriptyline in senile depression

Objective To explore the curative effects and safety of venlafaxine in senile depression. Methods 62 patients with senile depression were randomly divided into research group ( n=31, took venlafaxine) and control group (n = 31, took amitriptyline) for 6 week double-blind controlled study; clinical curative effects were assessed with the Hamilton Depression Scale (HAMD) and Clinical Global Impression (CGI), and adverse reactions with the Treatment Emergent Symptom Scale(TESS). Results venlafaxine and amitriptyline were equivalent curative effect, the former took effect faster than the latter did and had milder adverse reactions. Conclusion Venlafaxine has significant curative effect, better compliance, milder adverse reactions and higher safety, and deserves to be popularized clinically.